Actively Recruiting
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
Led by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Updated on 2025-02-24
300
Participants Needed
1
Research Sites
1021 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities
CONDITIONS
Official Title
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Treated with at least one infusion of lisocabtagene maraleucel (liso-cel) for relapsed or refractory follicular lymphoma (Grade 1, 2, or 3a) after drug approval
- Treatment followed the FDA-approved dosage and US prescribing information
You will not qualify if you...
- Currently participating in other investigational studies at the time of liso-cel infusion
- Treated with liso-cel for follicular lymphoma Grade 3b
- Treated with non-conforming CAR T-cell products
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CIBMTR
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
Research Team
B
BMS Study Connect Contact Center www.BMSStudyConnect.com
CONTACT
F
First line of the email MUST contain NCT # and Site #.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here